DOI: <https://doi.org/10.47391/JPMA.405>

Individualised cognitive behaviour therapy in patients of substance use disorders: three case studies

Mafia Shahzadi¹, Qasir Abbas²

1 DHQ Hospital Sheikhpura, Pakistan; **2** Department of Applied Psychology, Government College University Faisalabad, Faisalabad, Pakistan

Correspondence: Mafia Shahzadi **Email:** mafia.mahak@yahoo.com

Abstract

The current study aims to investigate the effectiveness of Cognitive Behaviour Therapy (CBT) in the treatment of patients with substance use disorders. Three diagnosed patients with substance use disorders were recruited —i.e. 305.20 (F12.10) cannabis use disorder, 291.81 (F10.239) alcohol withdrawal disorder and 292.0 (F11.23) opioid withdrawal disorder, respectively. The patients were detoxified and individual treatment plan was formulated on the basis of CBT. The CBT therapeutic outcomes were evaluated on the basis of pre- and post-assessment scores. Results indicate that CBT worked effectively in one-on-one session. CBT effectively worked to manage patients' anger, craving, stress, sleep hygiene and assertive behaviour. It is concluded that CBT is an effective approach to deal with patients' anger, stress, craving, sleep and assertive behaviour.

Keywords: Cognitive Behavioural Therapy; Cannabis Use Disorder; Alcohol Withdrawal Disorder; Opioid Withdrawal Disorder

Introduction

Substance use disorder (SUD) is a global psychiatric problem which has a high rate of mortality and morbidity¹. For example, some adults use alcohol

occasionally and some use it frequently, which causes deaths and others psychological as well as medical problems.² According to an estimate, in the United States around 55% adults of age 26 years consumed alcohol monthly and one fourth of the adults are involved in binge drinking which has harmful consequences.³ Moreover, in the US 15.1 million adults met diagnostic criteria for alcohol-use disorder in the past 12 months which causes numerous mental health problems among individuals.⁴ In Asian countries, the use of illicit drugs is increasing as well. In Asian countries drug prevalence is about 0.01% - 4.6%.⁵

The prevalence rate of substance use-related disorders is also high in Pakistan. According to a survey report by UNODC, 6.7% individuals used an illegal drug in the past year and 4.3% individuals are suffering from substance use disorders and they need urgent treatment. This rate is increasing. For example, it was estimated that in 1980, 50,000 individuals were using some sort of substance, which increased to 6.2 million in 2006, 8.1 million in 2011 and since 2013 drug abuse prevalence is increasing rapidly.⁶ In Pakistan, heroin was not virtually in use around the 1980s, while 1990s saw an increasing heroin use.⁷ The Ministry of Narcotics Control Pakistan and the United Nations Office on Drugs and Crime released a collaborative report on drug use in Pakistan in 2013. This report describes that cannabis is the most common drug used in Pakistan by people aged between 15 and 64, while opiate use (opium or heroin) is widespread in one percent of the population.⁸

Substance use disorders are treatable and manageable psychiatric problems. After detoxification, cognitive behaviour therapy (CBT) is an evidence-based therapy for substance use disorders. It can be given as group therapy but it is more effective in one-on-one sessions. CBT particularly targets patients' behavioural and cognitive problems. The current study was planned to investigate the effectiveness of CBT in patients of Cannabis use disorder, Alcohol withdrawal disorder and Opioid withdrawal disorder.⁹⁻¹⁰

Patients and Methods

After getting permission from the Ethical Review Committee, three cases were studied using case study method at the DHQ hospital Shekhupura from June 2018 to February 2019. After getting consent from the patients, treatment was started. In depth clinical interviews were conducted. Further, Alcohol Smoking and Substance Involvement Screening Test (ASSIT) and Addiction Severity Index (ASI) tests were used for screening and assessment of the patients. Patients' scores on both scales are shown in Table 1 and 2. Patients were diagnosed according to DSM-5. Patient "A" was a 29-year-old married man diagnosed with [305.20 (F12.10)] cannabis use disorder. Patient "B" was a 27-year-old man, diagnosed with [291.81 (F10.239)] alcohol withdrawal disorder. Patient "C" was a 20-year-old man, diagnosed with [292.0 (F11.23)] opioid withdrawal disorder. Further, 18 to 20 CBT-based therapeutic sessions were provided to each patient. Each CBT session was conducted as agenda-based session. Further, patients' follow up sessions were also conducted for three months and they were educated about the lapse and relapse preventions.

Pre- and post-screening tools: Novaco Anger Scale, a 25 item self-reported measure which assesses an individual's anger intensity in response to provoking situations, was used.¹¹ The test-retest reliability of NAS is .89. Furthermore, Brief Substance Craving Scale is an 8 items self-report tool that measures the level of craving for substance abuse.¹² Perceived Stress Scale was used to measure the perception of stress.¹³ Adolescent Sleep Hygiene Scale is a self-report measure which assesses overall sleep hygiene.¹⁴ Rathus Assertiveness Scale contains 30 items which are intended to assess an individual's level of assertiveness.¹⁵ Significant difference was found between pre- and post-testing scores. (Figure-1).

Discussion

Findings reveal that cognitive behaviour or therapy (CBT) played a significant role in reducing anger, craving, and stress in patients. (Table-3). Furthermore, it

increases the quality of sleep and assertive behaviour in patients. These findings are consistent with the findings of previous studies. CBT trials play a positive role in the treatment of cannabis use disorder and it becomes more effective when used along with medication.¹⁶ It is evidenced that the nature of SUD affects patients' physiological, psychosocial and social function and CBT substantially helps to treat these factors. Moreover, CBT is an evidence-based approach which has been identified as an effective cognitive and behavioural treatment approach for SUD patients. In this study, individualised CBT sessions were provided to SUD patients and the outcomes were effective.¹⁷ It was observed that CBT worked effectively with alcohol and opioid withdrawal disorders at the rehabilitation facility. After the detoxification process, patients felt more comfortable to stay in therapeutic sessions. A previous study has also shown that the combination of pharmacotherapy and CBT produce the best outcomes for treating patients with substances use disorder.

CBT is a goal-directed approach which focuses on the current position of patients and mainly targets the patient's maladaptive cognitive, behavioural and emotional patterns.¹⁵ Additionally, CBT techniques and planning of treatment particularly target the patient's core beliefs. If the patient's illogical and irrational beliefs change into logical and rational beliefs, the patient starts to believe that he is able to cope with his problems and his problems are manageable. In the current study, structured CBT sessions were conducted with the patients individually. Each session was formulated with a particular goal and agenda. The main focus was on the patients' cognitive restructuring, stress management, daily living functioning, and lapse-relapse preventions. Patients' cognitive and behavioral functioning significantly improved. It was also observed that they tried to cope with their problems such as craving. CBT work effectively with alcohol and illicit drugs.¹⁸ Research also revealed that the durability of treatment also affects the results. For instance, one study by Rawson and colleagues described that 60% of patients in CBT state gave clean

toxicology screens at 52-week follow-up.¹⁹ By following the CBT technique, a marked difference in the pre- and post-rating of the problems was noticed. It was also concluded that contingency is very effective in substance use disorder patients. Additionally, deficits in abilities for handling with antecedents and consequences of substances are measured as a major contributor to the development of SUDs. An individual with SUDs does not use appropriate skills to overcome life stressors in an effective way. The reduced use of trained habits and skills significantly leads to SUDs.²⁰

In this current research, the technique “skill training” also known as “skills building” was used on substance use disorder patients. In the process of skills building, the patient’s emotions, cognitive, behaviour, organisational, interpersonal and problem-solving deficits were targeted. The approaches that were based on patients’s individual differences were used. The patient’s connection with others was worked on because the opposite of addiction is not sobriety; in fact, it’s the connection with society. In the current research, the focus was on the patient's interpersonal skills as well. Interpersonal skills help to remove relationship complications, enhance effective communication and capability to use effective communication and social support. This support helps in obtaining abstinence and healthy relationship.²¹

Conclusion

It is concluded that Cognitive Behaviour Therapy is an effective treatment approach for the treatment of substance use disorders. It effectively works to improve the patients' cognitive, behavioural and occupational functioning.

Limitations of the study

The study is rich in information but has some limitations. The patients showed moderate level of interest in homework assignments, and wished to increase the session interval when they felt they are improving but this factor was controlled through continuous motivations. Moreover, the patients apparently had lower

level of family, social and moral support during treatment; it is felt that if these were present better results would be achieved.

Disclaimer: None

Conflict of Interest: None

Funding Sources: None

References

1. Harford TC, Yi HY, Grant BF. Other-and self-directed forms of violence and their relationships to DSM-IV substance use and other psychiatric disorders in a national survey of adults. *Comp Psyc*, 2013;54:731-739.
2. World Health Organisation, *Global Status Report on Alcohol and Health, 2018*. Retrived on May 9, 2020 from www.who.int/substance_abuse/publications/global_alcohol_report/en/.
3. Substance Abuse and Mental Health Services Administration, *Key substance use and mental health indicators in the United States: Results from the 2017 National Survey on Drug Use and Health (HHS Publication No. SMA 18-5068, NSDUH Series H-53)* (2018). Retreved on May 09, 2020 from www.samhsa.gov/data/.
4. Center for Behavioural Health Statistics and Quality, Substance Abuse and Mental Health Services Administration, *Key substance use and mental health indicators in the United States: Results from the 2015 National Survey on Drug Use and Health (HHS Publication No. SMA 16-4984, NSDUH Series H-51)* (2016); Retrieved on May 4, 2020 from www.samhsa.gov/data/.
5. Otto MW, Smits JAJ Reese HE. Combined psychotherapy and pharmacotherapy for mood and anxiety disorders in adults: Review and analysis. *Clinical Psychology: Sci & Prac*. 2005;12:72–86.

- 173 6. UNODC. Drug use in Pakistan. Ministry of Interior and Narcotics
 174 Control Division. Pakistan. 2013; Retrieved on May 9, 2020 from
 175 https://www.unodc.org/documents/pakistan/Survey_Report_Final_2013.pdf
- 176 7. United Nations. The Millennium Development Goals Report 2009. New
 177 York: United Nations Department of Economic and Social Affairs. 2009.
 178 Rerieved on May 9, 2020 from
 179 [https://www.un.org/en/development/desa/publications/millennium-development-goals-](https://www.un.org/en/development/desa/publications/millennium-development-goals-report-2009.html)
 180 [report-2009.html](https://www.un.org/en/development/desa/publications/millennium-development-goals-report-2009.html)
- 181 8. National Institute of Mental Health (NIMH). National Comorbidity
 182 Survey: Lifeline prevalence estimate, 2007. Retrieved on May 3, 2020
 183 from www.hcp.med.harvard.edu
- 184 9. Palpacuer C, Duprez R, Huneau A, Locher C, Boussageon R, Laviolle B,
 185 Naudet F. Pharmacologically controlled drinking in the treatment of
 186 alcohol dependence or alcohol use disorders: A systematic review with
 187 direct and network meta-analyses on nalmefene, naltrexone, acamprosate,
 188 baclofen and topiramate. *Addiction*, 2018; 113, 220–237
- 189 10. McHugh RK, Votaw VR, Barlow DH, Fitzmaurice GM, Greenfield SF,
 190 Weiss RD. Development of an integrated cognitive behavioural therapy
 191 for anxiety and opioid use disorder: Study protocol and methods.
 192 *Contemp Clin Trials*. 2017;60:105–112. doi:10.1016/j.cct.2017.07.006
- 193 11. Novaco RW. The Novaco Anger Scale and Provocation Inventory (NAS-
 194 PI) Manual. Los Angeles: Western Psychological Services. 2003.
 195 Retrieved on May 09, 2020 from
 196 [https://www.researchgate.net/publication/51214362_The_Novaco_Anger_Scale-](https://www.researchgate.net/publication/51214362_The_Novaco_Anger_Scale-Provocation_Inventory_1994_Version_in_Dutch_Forensic_Psychiatric_Patients)
 197 [Provocation_Inventory_1994_Version_in_Dutch_Forensic_Psychiatric_Patients](https://www.researchgate.net/publication/51214362_The_Novaco_Anger_Scale-Provocation_Inventory_1994_Version_in_Dutch_Forensic_Psychiatric_Patients)
- 198 12. Somoza E, Dyrenforth S, Goldsmith J, Mezinskis J, Cohen M. In search
 199 of a universal drug craving scale. Paper presented at the Annual Meeting
 200 of the American Psychiatric Association, Miami Florida. 1995;
- 201 13. Cohen S, Kamarck T, Mermelstein R. A global measure of perceived
 202 stress. *J Heal Soc Beh*. 1983;24: 386-396.

14. Storfer-Isser A, LeBourgeois MK, Harsh J, Tompsett CJ, Redline S. Psychometric Properties of the Adolescent Sleep Hygiene Scale (ASHS). *J Sleep Res.* 2013;22: doi:10.1111/jsr.12059
15. Rathus SA. A 30-item schedule for assessing assertive behaviour. *Behaviour Therapy*, 1973;4:398–406. doi: 10.1016/s0005-7894(73)80120-0.
16. Guven F M, Camsari U M, Senormanci O, Oguz G. Cognitive behavioural therapy in cannabis use disorder. In V. R. Preedy (Ed.), *Handbook of cannabis and related pathologies: Biology, pharmacology, diagnosis, and treatment* , 2017; p. 1056–1065. <https://doi.org/10.1016/B978-0-12-800756-3.00127-7>
17. Witkiewitz K, Litten RZ, Leggio L. Advances in the science and treatment of alcohol use disorder. *Sci. Adv.* 5, eaax4043 (2019). Retrieved on January 7, 2019 from <https://advances.sciencemag.org/content/5/9/eaax4043>
18. Powers MB, Vedel E, Emmelkamp MG. Behavioral couples therapy (BCT) for alcohol and drug use disorders: A meta-analysis. *Clin Psych Rev.* 2008; 28:952–962.
19. Carroll KM, Fenton LR, Ball SA. Efficacy of disulfiram and cognitive behavioral therapy in cocaine-dependent outpatients: a randomized placebo-controlled trial. *Arch Gen Psychiatry.* 2004;61:264-72
20. Walters D, Connor JP, Feeney GF, Young RM. The cost-effectiveness of naltrexone added to cognitive-behavioural therapy in the treatment of alcohol dependence. *J Addict Dis.* 2009;28:137–144.
21. Brian J. Sherman, Aimee L. McRae-Clark Pharmacotherapy. Author manuscript; available in PMC 2017 May 1. Published in final edited form as: *Pharmacotherapy.* 2016;36: 511–535. doi: 10.1002/phar.1747

Table 1: Scales Raw Scores on ASSIST of All Case Studies

<i>Substances</i>	<i>Case Study-1</i>		<i>Case Study-2</i>		<i>Case Study-3</i>	
	<i>Score</i>	<i>Risk Level</i>	<i>Score</i>	<i>Risk Level</i>	<i>Score</i>	<i>Risk Level</i>
Tobacco products	30	High	1	Low	35	High
Alcoholic Beverages	0	Low	32	High	12	Moderate
Cannabis	0	Low	0	Low	32	High
Cocaine	32	High	0	Low	1	Low
Amphetamine/ stimulants	1	Low	1	Low	0	Low
Inhalants	1	Low	0	Low	1	Low
Sedatives/ Sleeping Pills	15	Moderate	12	Moderate	20	Moderate
Hallucinogens	1	Low	0	Low	1	Low
Opioids	0	Low	0	Low	35	High
Other – specify	1	Low	0	Low	1	Low

ASSIT= Alcohol, Smoking and Substance Involvement Screening Test

Table 2: Scale Raw Scores on Addiction Severity Index of All Case Studies

<i>Problems</i>	<i>Case Study-1</i>	<i>Case Study-2</i>	<i>Case Study-3</i>
	Severity profile	Severity profile	Severity profile
Medical	3	2	3
Employment	5	8	2
Alcohol	0	7	1
Drug	9	9	9
Legal	1	2	2
Family/social	8	8	8
Psych	0	0	0

Table 3: Scales Raw Scores of Pre and Post Testing of All Case Studies

<i>Scales</i>	<i>Case Study-1</i>		<i>Case Study-2</i>		<i>Case Study-3</i>	
	<i>Pre-Testing</i>	<i>Post-Testing</i>	<i>Pre-Testing</i>	<i>Post-Testing</i>	<i>Pre-Testing</i>	<i>Post-Testing</i>
NAS	87	45	79	44	87	45
BSCS	31	11	25	8	32	17
PSS	37	21	35	24	39	26
ASHS	80%	50%	90%	50%	80%	60%
RAS	-85	-38	-76	-32	-78	-73

Note: NAS= Novaco Anger Scale; BSCS= Brief Substance Craving Scale; PSS= Perceived Stress Scale; ASHS= Adolescent Sleep Hygiene Scale; RAS= Rathus Assertiveness Scale

Figure 1: Graphical presentation of pre- and post-testing scores of three patients after Cognitive Behaviour Therapy